rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-3-19-25rpcardio-1108Research ArticleORIGINAL STUDIESОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯCOMPARATIVE EFFICACY OF ACE INHIBITORS (RAMIPRIL VS ENALAPRIL) IN TREATMENT OF CHRONIC HEART FAILURE IN WOMENСРАВНИТЕЛЬНАЯ ЭФФЕКТИВНОСТЬ ИНГИБИТОРОВ АПФ РАМИПРИЛА И ЭНАЛАПРИЛА В ЛЕЧЕНИИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У ЖЕНЩИНТерещенкоС. Н.TereshchenkoS. N.ЖировИ. В.ZhirovI. V.МаличенкоЕ. В.MalichenkoE. V.КазанцеваЕ. Э.KazantsevaE. E.Московский государственный медико-стоматологический университетРоссияMoscow State University of Medicine and DentistryRussian Federation200830012016431925Copyright © Tereshchenko S.N., Zhirov I.V., Malichenko E.V., Kazantseva E.E., 20162016Терещенко С.Н., Жиров И.В., Маличенко Е.В., Казанцева Е.Э.Tereshchenko S.N., Zhirov I.V., Malichenko E.V., Kazantseva E.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1108Aim

Aim. To compare clinical and haemodynamic efficacy of ramipril vs enalapril in women with chronic heart failure (CHF).

Material and methods

Material and methods. 60 women with non valvular CHF were included in the study. Patients were randomized in groups of ramipril or enalapril taken in addition to standard therapy. CHF severity, heart morphofunctional parameters, life quality, exercise tolerance, biomarkers (brain natriuretic peptide, von Willebrand factor) was estimated in patients initially and after 6 months of therapy.

Results

Results. Ramipril average daily dose was 11,4 mg, enalapril average daily dose - 34,2 mg. Dry cough was observed more rarely in patients treated with ramipril than in patients treated with enalapril. There was a trend to higher increase of exercise tolerance due to ramipril therapy in comparison with enalapril one (р=0,062). Ramipril, but not enalapril, reduced a number of patients with diastolic dysfunction (р=0,049). Life quality improvement was higher in ramipril treated patients in comparison with those treated with enalapril (р=0,04). Brain natriuretic peptide and von Willebrand factor levels decreased more significantly in ramipril therapy than in enalapril one (р=0,05 and р<0,05 , respectively).

Conclusion

Conclusion. Ramipril therapy of CHF in women has higher clinical efficacy and better tolerability in comparison with enalapril therapy.

Цель

Цель. Сравнить клинико-гемодинамическую эффективность рамиприла и эналаприла у женщин, страдающих хронической сердечной недостаточностью (ХСН).

Материал и методы

Материал и методы. В исследование включены 60 женщин с ХСН неклапанной этиологии. Пациентки рандомизированы в группы приема рамиприла и эналаприла в дополнение к стандартной терапии. Исходно и через 6 мес у пациенток определяли тяжесть ХСН, морфо-функциональные изменения сердца, качество жизни, толерантность к физической нагрузке, содержание биомаркеров: мозгового натрийуретического пептида (МНП) и фактора Виллебранда.

Результаты

Результаты. Средняя суточная доза рамиприла составила 11,4 мг, эналаприла – 34,2 мг. При приеме рамиприла достоверно реже наблюдался сухой кашель, явившийся причиной досрочного выбывания пациенток, принимавших эналаприл. При приеме рамиприла по сравнению с эналаприлом отмечалась тенденция к большему увеличению толерантности к нагрузке (р=0,062). На фоне терапии рамиприлом, в отличие от терапии эналаприлом, происходило достоверное уменьшение (р=0,049) частоты диастолической дисфункции по данным эхо- кардиографии. Отмечено более высокое улучшение качества жизни в группе рамиприла по сравнению с группой эналаприла (р=0,04). Снижение уровней МНП и фактора Виллебранда в группе рамиприла было более выраженным по сравнению с группой эналаприла (р=0,05 и р<0,05, соответственно). Заключение. Рамиприл в комплексной терапии ХСН у женщин обладает клиническими преимуществами по сравнению с эналаприлом и ха- рактеризуется лучшей переносимостью.><0,05, соответственно).

Заключение

Заключение. Рамиприл в комплексной терапии ХСН у женщин обладает клиническими преимуществами по сравнению с эналаприлом и характеризуется лучшей переносимостью.

хроническая сердечная недостаточностьгендерные различияингибиторы АПФchronic heart failuregender differencesACE inhibitorsReferencesOakley C. Peripartum cardiomyopathy. In: Women&Heart Disease, 2nd edition. Eds: Wenger N. and Collins P. London: Taylor&Francis; 2005.Oakley C. Peripartum cardiomyopathy. In: Women&Heart Disease, 2nd edition. Eds: Wenger N. and Collins P. London: Taylor&Francis; 2005.Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics. Clin Pharmacokinet 2002;41:329-42.Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics. Clin Pharmacokinet 2002;41:329-42.Weinberg E., Thienelt C., Katz S. et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 1999;34:264-73.Weinberg E., Thienelt C., Katz S. et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 1999;34:264-73.Pfeffer J., Pfeffer M., Fletcher P. et al. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol 1982;242:H776-H784.Pfeffer J., Pfeffer M., Fletcher P. et al. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol 1982;242:H776-H784.Carroll J., Carroll E., Feldman T. et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992;86:1099-107.Carroll J., Carroll E., Feldman T. et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992;86:1099-107.Aurigemma G., Gaasch W. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology 1995;86:310-7.Aurigemma G., Gaasch W. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology 1995;86:310-7.Mendez L., Davidoff R., Cupples L. Et al. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997;134:207-12.Mendez L., Davidoff R., Cupples L. Et al. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997;134:207-12.Krumholz H., Larson M., Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993;72:310-3.Krumholz H., Larson M., Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993;72:310-3.Guerra S., Leri A., Wang X. Et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999;85:856-66.Guerra S., Leri A., Wang X. Et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999;85:856-66.Olivetti G., Giordano G., Corradi D. et al. Gender differences and aging: effects on the human heart. J Am Coll Cardiol 1995;26:1068-79.Olivetti G., Giordano G., Corradi D. et al. Gender differences and aging: effects on the human heart. J Am Coll Cardiol 1995;26:1068-79.Fischer M., Baessler A., Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002;53:672-7.Fischer M., Baessler A., Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002;53:672-7.Jochmann N., Stangl K., Garbe E. et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular disease. Eur Heart J 2005;26:1585-95.Jochmann N., Stangl K., Garbe E. et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular disease. Eur Heart J 2005;26:1585-95.Shekelle P., Rich M., Morton S. et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38.Shekelle P., Rich M., Morton S. et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342(8875):821-8.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342(8875):821-8.Boneu B., Abbal M., Plante J., Bierme R. Factor VIII complex and endothelial damage. Lancet 1975;30:325-33.Boneu B., Abbal M., Plante J., Bierme R. Factor VIII complex and endothelial damage. Lancet 1975;30:325-33.Reidy MA, Chopek M, Chao S, et al. Injury induces increase of von Willebrand factor in rat endothelial cells. Am J Pathol 1989;134:857-864.Reidy MA, Chopek M, Chao S, et al. Injury induces increase of von Willebrand factor in rat endothelial cells. Am J Pathol 1989;134:857-864.Over J., Sixma J.J. et al. Survival of 125-iodine labeled factor VIII in normals and patients with classical hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978;62:223-34.Over J., Sixma J.J. et al. Survival of 125-iodine labeled factor VIII in normals and patients with classical hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978;62:223-34.Поливода С.Н., Черепок А.А. Фактор Виллебранда как маркер эн- дотелиальной дисфункции у пациентов с заболеваниями сердечно- сосудистой системы. Укр ревматол журн 2000;(7):13-7.Поливода С.Н., Черепок А.А. Фактор Виллебранда как маркер эн- дотелиальной дисфункции у пациентов с заболеваниями сердечно- сосудистой системы. Укр ревматол журн 2000;(7):13-7.Gao Z., Liu F., Yu Z. et al. Effects of von Willebrand factor concentration and platelet collision on shear-induced platelet activation. Thromb Haemost 2008;100(1):60-8.Gao Z., Liu F., Yu Z. et al. Effects of von Willebrand factor concentration and platelet collision on shear-induced platelet activation. Thromb Haemost 2008;100(1):60-8.Montalescot G., Philippe F., Vicaut E. and the French Investigators of the ESSENCE Trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Circulation 1998;98:294-9.Montalescot G., Philippe F., Vicaut E. and the French Investigators of the ESSENCE Trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Circulation 1998;98:294-9.Ewenstein B.M., Warhol M.J., Handin R.I., Pober J.S. Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol 1987;104:1423-33.Ewenstein B.M., Warhol M.J., Handin R.I., Pober J.S. Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol 1987;104:1423-33.Verweij C.L. Biosynthesis of human von Willebrand factor. Haemostasis 1988;18:224-45.Verweij C.L. Biosynthesis of human von Willebrand factor. Haemostasis 1988;18:224-45.Bowie E.J.W., Solberg L.A., Fass D.N. et al. Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J Clin Invest 1986;78:26-30.Bowie E.J.W., Solberg L.A., Fass D.N. et al. Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J Clin Invest 1986;78:26-30.Bellucci S., Ignatova E., Jaillet N., Boffa M.C. Platelet hyperactivation in patient with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the levels of plasma thrombomodulin? Protein S, PAI-1, tPA and vWF. Thromb Haemost 1993;70:736-42.Bellucci S., Ignatova E., Jaillet N., Boffa M.C. Platelet hyperactivation in patient with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the levels of plasma thrombomodulin? Protein S, PAI-1, tPA and vWF. Thromb Haemost 1993;70:736-42.Green D., Kucuk O., Haring O., Dyer A. The factor VIII complex in atherosclerosis: effects of aspirin. J Chron Dis 1982;34:21-26.Green D., Kucuk O., Haring O., Dyer A. The factor VIII complex in atherosclerosis: effects of aspirin. J Chron Dis 1982;34:21-26.

The authors declare that there are no conflicts of interest present.